

Program

May 10 (Tue.)

Animal Prion Diseases Workshop



"Updated Diagnosis and Epidemiology of Animal Prion Diseases for Food Safety and Security"

(Sponsored by the OECD Co-operative Research Programme)

9:00-9:05 **Opening Remarks**

9:05-9:15 OECD programme

Rafael Blasco INIA-Ministerio de Ciencia e Innovacion

9:15-10:50 Workshop 01-04

- Chairs: Motohiro Horiuchi (Hokkaido University) Corinne Lasmezas (The Scripps Research Institute)
- WS-01 Prion diseases in animals and zoonotic potential Juan Maria Torres Centro de Investigacion en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain

WS-02 Scrapie in swine: A diagnostic challenge Justin J Greenlee

National Animal Disease Center, US Dept. of Agricultrue, Agricultural Research Service, United States

WS-03 Epidemiology of Chronic wasting disease in Korea Hyun-Joo Sohn

Foreign Animal Disease Division (FADD), Animal and Plant Quarantine Agency (QIA), Korea

WS-04 Ultra-sensitive detection of PrP^{sc} of classical and atypical BSEs Yuichi Murayama Influenza/Prion Disease Research Center, National Institute of Animal Health, Japan

10:50-12:45 Workshop 05-08

Chairs: Yoshifumi Iwamaru (National Institute of Animal Health) Jean Manson (The Roslin Institute, University of Edinburgh)

WS-05 **RT-QuIC Assays in Humans and Animals** Steven J Collins The University of Melbourne, Australia

WS-06 Pathology of TSEs

John Spiropoulos

Animal and Plant Health Agency, Pathology Department, United Kingdom

WS-07 Diagnosis of Atypical BSE and Isolation of the Agent

Sandor Dudas

Canadian National and OIE BSE Reference Laboratory, Canadian Food Inspection Agency, National Center for Animal Disease, Lethbridge, Canada

WS-08 Intra- and interspecies transmission of atypical BSE - What can we learn from it? Anne Balkema-Buschmann

Friedrich-Loeffler-Institut, Institute for Novel and Emerging Infectious Diseases, Germany

12:45-13:30 Luncheon Seminar 1 "Prion treatment by MC Water and other chemicals"

*Co-sponsored by Santa Mineral Co., Ltd.

Chair: Koriki Jojima (Former Minister of Finance) Speakers: Takashi Onodera (Professor of University of Tokyo) Kouichi Furusaki (General incorporated association Mineral Activation Technical Research Center)

13:30-15:00 Workshop 09-11

Chairs: Hiroyuki Okada (National Institute of Animal Health) John Spiropoulos (Animal and Plant Health Agency)

WS-09 Pathogenesis and transmission of classical and atypical BSEs in cattle Cristina Casalone

Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Italy

WS-10 Neuronal death and prion diseases

Corinne Lasmezas

Department of Immunology and Microbial Science, Department of Neuroscience, The Scripps Research Institute, United States

WS-11 Evaluating the species barriers of TSEs with transgenic mouse models Jean C Manson

The Roslin Institute, University of Edinburgh, United Kingdom

15:00-15:30 Closing Discussion

Chairs: Toshiro Kawashima (Ministry of Agriculture, Forestry and Fisheries, Japan) Takashi Yokoyama (National Institute of Animal Health, NARO)

15:45-16:15 **Opening Lecture**

Chair: Motomasa Tanaka (RIKEN Brain Science Institute, Lab for Protein Conformation Diseases)

OL-01 Implications of the folded in-register parallel beta-sheet structure of infectious prion amyloids

Reed B. Wickner

National Institutes of Health; National Institutes of Diabetes and Digestive and Kidney Diseases; Laboratory of Biochemistry and Genetics, United States

16:15-16:45 **Opening Lecture**

Chair: Naomi Hachiya (Tokyo Medical University)

OL-02 PrP^c function and prion toxicity

Adriano Aguzzi Institute of Neuropathology, University Hospital of Zürich, Schmelzbergstrasse, Zürich, Switzerland



May 11 (Wed.)

9:00-11:00 Invited Lectures "Conversion and Propagation"

Chairs: Noriyuki Nishida (Molecular Microbiology and Immunology, Nagasaki University) Glenn Telling (Colorado University)

IL-01 Molecular Determinants of Prions Infectivity

Giuseppe Legname

Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy

IL-02 Potential role of the environment on prion transmission: Plants, environmental surfaces and earthworms as carriers of infectious prions

Claudio Soto

Mitchell Center for Alzheimer's Diseases and Related Brain Disorders, Department of Neurology, University of Texas Medical School at Houston, United States

IL-03 How does recombinant prion protein become infectious? Progress in understanding the molecular basis of prion infectivity Jiyan Ma

Van Andel Institute, United States

IL-04 Sorting of prion protein and PrP^{sc} accumulation

Keiji Uchiyama

Institute for Enzyme Research, Tokushima University, Japan

11:15-12:00 **Oral Session**

O-01 Folding and misfolding pathways of prion protein

Ryo P. Honda

Department of Molecular Pathobiochemistry, Gifu University Graduate School of Medicine, Japan

O-02 HET-2s, an engineered, four-rung beta-solenoid protein as a model for the structure of PrPSc

Holger Wille

Centre for Prions & Protein Folding Diseases, Canada

O-03 Prion protein deficiency causes diverse proteome shifts in cell models that escape detection in brain tissue

Mohadeseh Mehrabian

Tanz Centre for Research in Neurodegenerative Diseases; Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada

12:10-13:00 Luncheon Seminar 2 "From prion diseases to Alzheimer's disease"

*Co-sponsored by Daiichi Sankyo Co., Ltd.

Chair: Hidehiro Mizusawa (President / National Center of Neurology and Psychiatry) Speaker: Masahito Yamada (Professor and Chairman / Department of Neurology & Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences)

13:00-14:30 Invited Lectures "Pathogenesis I"

Chairs: Byron Caughey (LPVD, Rocky Mountain Labs, NIAID, NIH) Shigeo Murayama (Tokyo Metropolitan Institute of Gerontology)

IL-05 Prion structures, PIRIBS architectures, and real-time quaking-induced conversion (RT-QuIC)

Byron Caughey LPVD, Rocky Mountain Labs, NIAID, NIH, United States

IL-06 Neuropathology of prion disease

James W Ironside National CJD Research & Surveillance Unit, University of Edinburgh, UK

IL-07 latrogenic transmission of Creutzfeldt-Jakob disease

Atsushi Kobayashi

Laboratory of Comparative Pathology, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan

14:45-16:15 Invited Lectures "Expansion of prion concept"

Chairs: Hidehiro Mizusawa (NCNP) Joaquin Castilla (Proteomic, CICbioGUNE, Spain)

IL-08 Revisiting supersaturation as a factor determining amyloid fibrillation Yuji Goto

Institute for Protein Research, Osaka University, Japan

IL-09 Mechanisms of prion protein (mis) folding and aggregation explored by ultrafast kinetics

Heinrich Roder Fox Chase Cancer Center, United States

IL-10 Tau / TDP-43 prions

Masato Hasegawa

Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan

16:15-17:00 **Oral Session**

O-04 Protein Folding Activity of the Ribosome: Key Player in Yeast Prion Propagation Cecile P Voisset

Inserm UMR 1078, University of Medecine of Brest, Etablissement Français du Sang (EFS) Bretagne, France; CHRU Brest, Morvan Hospital, Molecular Genetic Laboratory, Brest, France

O-05 A local conformation of natively disordered yeast prion monomer determines interspecies prion transmissibility

Toshinobu Shida

Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan; Laboratory for Protein Conformation Diseases, RIKEN Brain Science Institute, Wako, Japan

O-06 Prion nucleation and propagation by amyloid beta in the yeast model

Yury O. Chernoff

School of Biology, Georgia Institute of Technology, Atlanta, GA, USA; St. Petersburg State University, Russia



May 12 (Thu.)

9:00-10:30 Invited Lectures "Pathogenesis II"

Chairs: Shirou Mohri (Department of Neurological Science, Tohoku University Graduate School of Medicine)

Jean Manson (Neurobiology, The Roslin Institute, University of Edinburgh)

IL-11 Desigh of novel anti-prion compounds Steven H. Olson UCSF

IL-12 Activation state of glial cells in prion diseases Motohiro Horiuchi

Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan

 IL-13
 Transmission of prions to non human-primates: Implications for human populations

 Jean-Philippe Deslys
 CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Division of Prions and Related Diseases (SEPIA),

10:45-12:00 **Oral Session**

Fontenay-aux-Roses, France

O-07 Oral prion pathogenesis is reduced in the absence of CXCR5-expressing mononuclear phagocytes

Neil A. Mabbott The Roslin Institute & R(D)SVS, University of Edinburgh, UK

O-08 Tau pathology in Creutzfeldt-Jakob disease: Novel insights Gabor G. Kovacs

Medical University of Vienna, Institute of Neurology, Austria

O-09 Creutzfeldt-Jakob disease prion propagation in human iPS cells-derived astrocytes

Zuzana Krejciova

Institute for Neurodegenerative Diseases, University of California, San Francisco, United States; National CJD Research & Surveillance Unit, University of Edinburgh, United Kingdom

O-10 Role of Tunneling Nanotubes (TNTs) in intercellular spreading of prions and other protein

Chiara Zurzolo

Pasteur Institute, Department of Cell Biology and Infection, France

O-11 Structural role of the middle region in the prion protein in conformational conversion to the infectious form

Witold K Surewicz

Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA

12:10-13:00 Luncheon Seminar 3 "Clinicopathological Feature of Genetic Prion Diseases in Japan"

*Co-sponsored by Novartis Pharma K.K.

Chair: Yoshio Tsuboi (Professor of Department of Neurology, Fukuoka University) Speaker: Nobuo Sanjo (Associate Professor of Department of Neurology and Neurological Science, Tokyo Medical and Dental University)

Invited Lectures "Human Prion Diseases: Diagnosis" 13:00-14:30

Chairs: Michael D. Geschwind (Neurology, University of California, San Francisco) Ichirou Takumi (Nippon Medical School)

IL-14 Variant CJD

Robert G Will National CJD Research and Surveillance Unit, United Kingdom

IL-15 Genetic prion diseases

Inga Zerr

National CJD Surveillance Center, Dept. of Neurology, Georg August University Göttingen, Germany

IL-16 Biomarkers for prion disease

Piero Parchi

Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Italy; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

Oral Session 14:45-15:30

O-12 PrPSc in the skin of CJD patients

Wenguan Zou

Case Western Reserve University, United States

O-13 Autopsy validation of second generation RT OuIC for diagnosis and differentiation of human prion diseases: Results from the US National Prion Disease Pathology Surveillance Center

Jiri G. Safar National Prion Disease Pathology Surveillance Center, Case Western Reserve University, United States

O-14 Highly sensitive and specific detection of prions in blood of vCJD patients by PMCA Luis M Concha-Marambio

University of Texas Health Science Center, United States; Universidad de Los Andes, Facultad de Medicina, Chile

Invited Lectures "Animal Prion Diseases" 15:30-16:30

Chairs: Motohiro Horiuchi (Graduate School of Veterinary Medicine, Hokkaido University) Candace Mathiason (Microbiology, Immunology and Pathology, Colorado State University)

IL-17 Emergence of a novel bovine spongiform encephalopathy (BSE) prion from an atypical H-type BSE: An artificial laboratory strain or possible risk?

Takashi Yokoyama National Insitute of Animal Health, NARO, Japan

IL-18 Rapid analysis of prion seeding activity in clinically accessible biological samples using magnetic particle extraction and realtime conversion

Edward A Hoover Microbiology, Immunology, Pathology, Colorado State University, United States

Oral Session 16:30-17:00

O-15 Zoonotic Potential of CWD Prions: An Update

Qingzhong Kong Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

O-16 Puzzling out the BSE-human transmission barrier Natalia Fernandez-Borges CISA-INIA, Valdeolmos, Madrid, Spain



May 13 (Fri.)

9:00-11:00 Invited Lectures-APPS 2016 "Human Prion Diseases: Surveillance"

Chairs: Steve John Collins (Medicine, University of Melbourne, Australia) Yoshikazu Nakamura (Department of Public Health, Jichi Medical University)

IL-19 Epidemiological and clinical features of human prion diseases in Japan: Prospective 17year surveillance

Masahito Yamada

Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan

IL-20 Chinese surveillance program for prion diseases

Xiao-Ping Dong

State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

IL-21 Surveillance of prion diseases in Taiwan Shun-Sheng Chen Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Taiwan

IL-22 Real-time quaking-induced conversion analysis for the diagnosis of sporadic Creutzfeldt-Jakob disease in Korea

Yong-Sun Kim

Ilsong Institute of Life Science, Hallym University, Department of Neurodegenerative Diseases, Korea CJD Diagnostic Center, Korea

11:15-12:05 Oral Session "APPS Cutting-edge young researcher"

O-17 Acceleration of Abeta brain amyloidosis by peripheral administration of disease associated aggregates

Rodrigo Morales

The University of Texas Health Science Center at Houston, United States

O-18 Amyloid beta pathology in iatrogenic Creutzfeldt-Jakob disease: A multi-center study Ignazio Cali

Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, USA

O-19 Prion acute synaptotoxicity at the CA1 region of the stratum radiatum

Simote T Foliaki

Department of Medicine, The University of Melbourne, Australia

O-20 Neuron and glial cell type-specific detection of PrPSc in prion-infected mouse brain by flow cytometry

Takeshi Yamasaki

Chair: TBD

Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan

12:10-13:00 Luncheon Seminar 4 "α-Synuclein prions"

*Co-sponsored by GlaxoSmithKline K.K.

Speaker: Masato Hasegawa (Department Head, Department of Dementia and Higher Brain Function Tokyo Metropolitan Institute of Medical Science)

Invited Lectures "Human Prion Diseases: Treatment" 13:00-15:00 Chairs: Neil Roy Cashman (Medicine (Neurology), University of British Columbia) Yoshio Tsuboi (Fukuoka University) IL-23 Therapeutic approaches to prion infection and disease John Collinge MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology and National Prion Clinic, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom IL-24 Lessons from recent outcomes of clinical trials and therapeutic studies Katsumi Doh-ura Department of Neurochemistry, Tohoku University Graduate School of Medicine, Japan IL-25 Prevention Trial in Fatal Familial Insomnia Fabrizio Tagliavini IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy IL-26 Logical design of a therapeutic agent for prion diseases Kazuo Kuwata United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Japan **Oral Session** 15:15-16:00 0-21 Towards prophylactic treatments for carriers of pathogenic PrP mutations **Ruth Gabizon**

Department of Neurology, Hadassah University Hospital, Israel; Granalix

0-22 Eradication of PrPSc by poly-L-arginine in cells infected with prions Muhammad Wagas Hanyang University, Korea

O-23 Pre-implantation exclusion of embryos at risk for prion diseases Vardiella Meiner

Hadassah Hebrew University Hospital, Israel



Poster Session

May 11 (Wed.)-May 12 (Thu.) 17:15-19:15

P-001	Employing Dynamic Mass Redistribution to Identify Pharmacological Chaperones for The Cellular Prion Protein
	Saioa R. Elezgarai Department of Molecular Biochemistry and Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Spain; Dulbecco Telethon Institute, Centre for Integrative Biology (CIBIO), University of Trento, Trento, Italy
P-002	Using small molecule reagents to help distinguish among prion structural models Christopher J. Silva United States Department of Agriculture, ARS, WRRC, United States
P-003	PrP, in conjunction with CD21/35, bolsters B lymphocyte antibody responses, yet infectious prions utilize this system for lymphoid replication Sarah J Kane
	Colorado State University, United States
P-004	Structural characterisation of ex vivo mammalian prions isolated from multiple strains Cassandra I.J Terry MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology, United Kingdom
P-005	Lack of stress protection by the cellular prion protein: An alternative role in regulating growth factor signalling Andrew R Castle Roslin Institute, University of Edinburgh, Edinburgh, UK
P-006	Structural and folding studies of the protective V127 variant of human prion protein Laszlo LP Hosszu MRC Prion Unit, United Kingdom
P-007	Non-equivalent binding sites for Abeta1-40 on PrP determine the oligomerisation pathway
	Katarina Grznarova Brain and Spine Institute Paris, France; INRA/ National Institute of Agronomic Research, Molecular Virology and Immunology (VIM), Protein Macro-assembly and prion diseases (MAP2), Domaine de Vilvert, Jouy-en-Josas, France; CEA/French Alternative Energies and Atomic Energy Commission, Institute of Emerging Diseases, Innovative Therapies (SEPIA), Fontenay-aux-Roses, France
P-008	Proteolytic shedding of PrP ^c : Giving a little to gain a lot?
	Hermann C Altmeppen Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
P-009	Calibration of ultrasonic power and conformational analysis of MoPrP amyloid fibrils Kei-ichi Yamaguchi United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Japan; Center for Emerging Infectious Diseases, Gifu University
P-010	Polymorphism Analysis of Prion Protein Gene in Eleven Pakistani Goat Breeds Mohammad Farooque Hassan China Agricultural University, Beijing, China; SBBUVAS, Sakrand Sindh Pakistan
P-011	Matrix metalloprotease processing of the prion protein Victoria Lewis Department of Medicine, RMH, The University of Melbourne, Australia

P-012	A ZIP6-ZIP10 heteromer interacts with NCAM1, controlling its phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition Dylan Brethour Tanz Centre for Research in Neurodegenerative Diseases; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada
P-013	Dimer-sized PrPSc formation detected by western blotting Kenta Teruya Department of Neurochemistry Tohoku University Graduate School of Medicine, Japan
P-014	The Prion Protein and genotoxic stress Malin R. Reiten Norwegian University of Life Sciences, Norway
P-015	Effects of cell growth suppression treatments on PrPSc accumulation in prion-infected cells; Paradoxical phenomena observed in butyric acid treatment Takako Hiyoshi Department of Neurochemistry, Tohoku University Graduate School of Medicine, Japan
EP-001	A novel system for massively parallel, quantitative analysis of PrP interactions and binding interfaces Stefanie M. Berges University of Delaware, United States
EP-002	The influence of Prnpb polymorphisms and the conserved 4-threonine stretch of Alpha-helix 2 on prion protein conversion Romany Abskharon Van Andel Research Institute, United States; National Institute of Oceanography and Fisheries (NIOF), Cairo, Egypt
EP-003	Solubilization of the aggregated-prion protein with the robust protein-unfolding activity of an oligomeric form of YDL178wp/ Unfoldin Naomi Hachiya Tokyo Medical University, Pathophysiology, Japan
P-016	Manipulation of Autophagic machinery Controls Exosomal Release of Prions and Lateral Prion Infection Basant A Abdulrahman Department of Camparative Biology and Experimental Medicine, Canada
P-017	Semisynthesis of lipidated prion protein variants Stefanie Hackl Institute of Biological Chemistry, Department of Chemistry, University of Vienna, Waehringer Str., Vienna, Austria
P-018	In vitro seeding of amyloid plaques Kirsty A Ireland The Roslin Institute, United Kingdom
P-019	Discovery of anti-prion agents using a PyMOL plugin-based logical drug design platform NAGARA Biao Ma United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan
P-020	Zinnia elegans combined PrP ^{BSE} complex increases the survival time of VM mice Hyo Jin Kim Foreign Animal Disease Division, Animal and Plant Quarantine Agency, Korea
P-021	Gene expression profiling analysis of <i>Rubus coreanus Miquel</i> -cured prion-infected MDBK cell line Hyo Jin Kim Foreign Animal Disease Division, Animal and Plant Quarantine Agency, Korea




P-022	The effects of PrPC glycosylation and cofactor molecules on species-specific prion strain susceptibility in the bank vole
	Cassandra M Burke Department of Biochemistry, Geisei School of Medicine at Dartmouth, Hanover, New Hampshire, United States
P-023	Autophagy is needed in opposing roles in the life cycle of prions and also impacts exosomal release of prions
	Hermann M Schatzl University of Calgary, Comp. Biol. & Exp. Med., Canada
P-024	Polymorphism of PrP amyloid-like fibrils can be defined by the concentration of seeds
	Vytautas Smirnovas Vilnius University Institute of Biotechnology, Dept. Biothermodynamics and Drug Design, Lithuania
P-025	Restricted propagation of sheep scrapie in hamsters
	Ronald A Shikiya Creighton University, Medical Microbiology and Immunology, United States
P-026	Comparison of the <i>in vitro</i> seeding activity of UK iatrogenic and sporadic Creutzfeldt- Jakob disease subtypes by real time quaking induced conversion
	Alexander H Peden National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom
P-027	PrP glycosylation-independent amplification of prions using highly efficient cell-based protein misfolded cyclic amplification
	Mohammed Moudjou INRA, UR892, Virologie Immunologie Moleculaires, Jouy-en-Josas, France
P-028	Validating human stem cell derived neural cultures as a flexible model system in which to investigate neurodegenerative mechanisms
	James D Alibhai The National CJD Research and Surveillance Unit, Centre for Clinical Brain Sciences, The University of Edinburgh, United Kingdom
P-029	sCJD prion seeding activity in human urine by RT-QuIC
	Gabriele Piconi National CJD Research and Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
P-030	Comparison of the in vitro amplification efficiency of UK iatrogenic and sporadic Creutzfeldt-Jakob disease subtypes by protein misfolding cyclic amplification
	Marcelo Barria Matus National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, The University of Edinburgh, United Kingdom
P-031	Determination of the amino terminal domains of the cellular prion protein that are required for highly efficient prion propagation
	Parineeta Arora MRC, United Kingdom
P-032	Prion-type dependent deposition of PRNP allelic products: Study in scrapie and BSE infected heterozygous ARR/VRQ sheep
	Jan PM Langeveld Central Veterinary Institute part of WageningenUR, Netherlands
P-033	PrP quaternary structure and prion capacity to cross the species barrier Angelique Igel INRA UR892 VIM, France
P-034	Influence of a polymorphism in the highly conserved hydrophobic core region on
	chronic wasting disease prion propagation and pathogenesis Samia Hannaoui University of Calgary, Faculty of Veterinary-Medicine, Dept. of Ecosystem and Public Health, Canada

P-035	From misfolding to aggregation: Sequence effects on conformational properties of amyloidogenic peptides implicated in neurodegeneration Nikolay Blinov
	National Institute for Nanotechnology, Canada; Department of Mechanical Engineering, University of Alberta, Alberta, Canada
P-036	Modulation of protein quality control pathways as a novel intervention strategy in prion diseases
	Simrika Thapa Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Canada
P-037	Effect of substitutions equivalent to bank vole 109I polymorphism in the spontaneous misfolding ability of PrPs from several mammalian species Hasier Erana
	CIC bioGUNE, Parque Tecnologico de Bizkaia, Derio, Spain
P-038	Differences in the denatured state of wild-type and E211K bovine PrP Eric M Nicholson USDA / Agricultural Research Service / National Animal Disease Center, United States
P-040	Cellular phenotypes of prion disease in skin-derived fibroblasts of asymptomatic PrP
	mutation carriers and sporadic CJD patients
	Wenquan Zou Case Western Reserve University, Pathology, United States
P-041	Gerstmann-Sträussler-Scheinker diseases with P102L, A117V and F198S mutations transmit efficiently and produce distinct pathological phenotypes in bank voles
	Laura Pirisinu Istituto Superiore di Sanità, Dept. of Veterinary Public Health and Food Safety, Italy
P-042	Identification of the origin of Creutzfeldt-Jakob disease after cadaver-sourced pituitary growth hormone treatment using an amplification property in protein misfolding cyclic amplification
	Atsuko Takeuchi Department of Neurological Science, Tohoku University Graduate School of Medicine, Japan
P-043	Curing PrP-sc by a gene-interference strategy targeting biosynthesis of undersulfated heparan sulphate
	David Cullis-Hill Sylvan Scientific Pty Ltd., Australia
P-044	Kinetics of RML prion propagation in three inbred mouse strains with indistinguishable expression levels of PrP ^c but distinct incubation periods
	Malin K Sandberg MRC Prion Unit, Department of Neurodegenerative Disease, United Kingdom
P-045	A cellular bioluminescence assay detects prion protein dimerization and aggregation upon infection
	Gültekin Tamgüney German Center for Neurodegenerative Diseases (DZNE), Germany
P-046	Altered dynamics of membrane microdomain distribution in chronically prion-infected cells
	Peter C. Kloehn UCL Institute of Neurology, MRC Prion Unit, United Kingdom
P-047	A Comprehensive Study of The Potential Resistance of The Canidae Family to Prion Infection
	Natalia Fernandez-Borges CISA-INIA, Carretera de Algete a El Casar s/n, Valdeolmos, Madrid, Spain; CIC bioGUNE, Derio, Bizkaia, Spain

ار PRION 2016 T●KYO	5
P-048	Classification of anti-prion compounds based on the binding properties to prion proteins
	Yuji O. Kamatari Life Science Research Center, Gifu University, Japan
P-049	A platinum compound targeting the cysteine residues of disease-related form of prion protein in cell lysates Yuji Sakasegawa Department of Neurochemistry, Tohoku University Graduate School of Medicine, Japan
EP-004	Single Molecule Studies of Protein Aggregates in Prion Diseases Chieh Sang Department of Chemistry, University of Cambridge, United Kingdom
EP-005	Creutzfeldt-Jakob disease in Korea
	Jeong Ho Park Ilsong Institute of Life Science, Hallym University, Korea; Korea CID Diagnostic Center, Hallym University
EP-006	Jakob disease
	Kenji Sakai Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Japan
EP-007	Post-translational modifications in the prion protein determine disease outcome Christina Sigurdson Pathology, University of California, United States
EP-008	A self-propagating protease-resistant baculovirus-derived recombinant prion protein is spontaneously generated by protein misfolding cyclic amplification at high temperature
	Morikazu Imamura National Institute of Animal Health, Japan
EP-009	Emergence and Host Dependent Propagation of Chronic Wasting Disease strains Camilo Duque Center for Prions and Protein Folding Diseases, Canada
P-050	A kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading
	Marija Iljina Chemistry Department, University of Cambridge, United Kingdom
P-051	Proteomic screening and identification of a structural protein of [NSI+] prion determinant in yeast Saccharomyces cerevisiae
	Anton A. Nizhnikov Dept. of Genetics and Biotechnology, St. Petersburg State University; St. Petersburg Branch, Vavilov Institute of General Genetics, Russian Academy of Sciences, Universitetskaya nab, St. Petersburg, Russia
P-052	Aggregation of QN-rich fragment of Gln3 in yeast Saccharomyces cerevisiae is modulated by [PSI+] and [PIN+] prions
	Kirill S. Antonets Dept. of Genetics and Biotechnology, St. Petersburg State University, Russian Federation; St. Petersburg Branch, Vavilov Institute of General Genetics, Russian Academy of Sciences
P-053	Prion-like Proteins and Disease Propagation in ALS Neil R Cashman Neurology, University of British Columbia, Canada

P-055	Yeast-based Search for New Human Amyloidogenic Proteins Nina V. Romanova St Petersburg State University, St Petersburg, Russia
P-056	Analysis of Interspecies Prion Transmission in Yeast Aleksandr A. Rubel St Petersburg State University, St Petersburg, Russia
P-057	Formation of a metastable stress-inducible prion by the yeast short-lived actin associated protein Tatiana A. Chernova Department of Biochemistry, Emory University School of Medicine, Atlanta, USA
P-058	Emergence and evolution of prion and prion-like proteins in the eukaryotic domain Paul M Harrison McGill University, Dept. of Biology, Canada
P-059	Latent structural variation in a yeast prion monomer determines strain phenotypes Motomasa Tanaka RIKEN Brain Science Institute, Japan
P-060	Chaperone sorting factor Cur1 exhibits differential effects on yeast prions Galina A. Zhouravleva Dept. of Genetics and Biotechnology, St Petersburg State University, Russian Federation; Laboratory of Amyloid Biology, St Petersburg State University
P-061	Modulation of Yeast Prion Strain Competition by Host Genetic Background and Molecular Chaperons Chang-I Yu
	Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, R.O.C.; Department of Life Sciences and Institute of Genomic Sciences, National Yang-Ming University, Taipei, Taiwan, R.O.C.
P-062	Prophylactic efficacy of orally administered compounds on the progression of scrapie induced motor coordination deficits Damani N Bryant
P-063	Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, United States We shall overcome prion diseases only by using both scientific and empiric findings or why honoring discovery and development of avermectins with 2015 Nobel Prize for physiology or medicine does not decrease their chronic toxicity especially neural degeneration increasing the susceptibility for prion diseases Andreas Becker Independent Institute for Holistic Prion Research, Germany
P-064	Low activity of complement in the cerebrospinal fluids of the patients with various prion diseases Cao Chen State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and
	Prevention, Chinese Center for Disease Control and Prevention, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University
P-065	Myelin basic protein citrullination as predictive marker of demyelination contributes to the pathogenesis of prion diseases Byungki Jang
	Ilsong Institute of Life Science, Hallym University, Anyang, Korea
P-066	Emergence of two prion subtypes in ovine PrP transgenic mice infected with human MM2-cortical Creutzfeldt-Jakob disease prions Vincent Beringue
	INRA, France



University of Alberta, Dept. of Agricultural, Food and Nutritional Science, Canada

P-079	Effect of scrapie infection on expression of endogenous retroviral genes in sheep lymphoid tissues Fiona Houston The Roslin Institute, United Kingdom
P-080	Early Age Oral Administration of Mouse Recombinant Prion Protein Resistant or RML Trigger Lifelong Modifications in the Composition of Intestinal Microbiota in FVB/N Female Mice Suzanna M Dunn University of Alberta, Department of Agricultural, Food and Nutritional Science, Canada
P-081	Importance of Complement Receptor CD21 in Establishing Peripheral Prion Accumulation Eric M Swanson Colorado State University, United States
P-082	Infectious CWD prions detected at the feto: Maternal interface of experimental and free-range naturally-exposed cervids Candace K Mathiason Microbiology, Immunology and Pathology, United States
P-083	Prion strain-dependent effect of macroautophagy on abnormal prion protein degradation Daisuke Ishibashi Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan
P-084	Differential effects of anti-prion treatments highlight differences in the pathogenesis of sporadic and familial forms of prion disease and identifies novel mode of action for pentosan polysulfate Victoria A Lawson Department of Pathology, The University of Melbourne, Australia
P-085	Withdrawn
P-086	Neuropathological analysis of hyperintense signals on magnetic resonance imaging in MM1+2 type sporadic Creutzfeldt-Jakob disease Ayano Shima Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan
P-087	HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt- mTOR pathway Lifeng Yang National Animal Transmissible Spongiform Encephalopathy Laboratory, China Agricultural University, Beijing, China
P-088	Transmission of experimental CH1641-like scrapie to bovine PrP overexpression mice Kohtaro Miyazawa Influenza and Prion Disease Research Center, National Institute of Animal Health, NARO, Japan
EP-014	Progranulin: Potential regulator in pathogenesis of Prion disease? Hee-Young Lim Hallym University, Ilsong Institute of Life Science, Korea
EP-015	Pathognomonic inter-tissue transcriptome analysis following prion spread by intraperitoneal infection Yeong-Gon Choi Ilsong Institute of Life Science, Hallym University, Korea



EP-016	Characterization of newly established neuronal cell lines from Bank Vole prion protein transgenic mice
	Hong-Seok Choi Ilsong Institute of Life Science, Hallym University, Korea
EP-017	Comparison of abnormal isoform of prion protein in prion-infected cell lines and primary cultured neurons by PrP ^{sc} -specific immunostaining
	Misaki Tanaka Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan
EP-018	RNA editing: A novel approach to understand CJD pathogenesis
	Eirini Kanata Prion Diseases Research Group, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Greece
EP-019	Interspecies transmission of atypical L-BSE prion to non-human primates (cynomolgus macaques) alleviates PrPSc glycoform profile of cattle L-BSE trait, but preserves incompetent transmissibility to inbred mice
	Ken'ichi Hagiwara Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Japan
P-089	New CSF-based approaches in the differential diagnostic of sCJD
	Franc Llorens German Center for Neurodegenerative Diseases, Germany; Department of Neurology, Clinical Dementia Center, University Medical Center Gottingen, Germany
P-090	Identification of microRNA signature in sCJD reveals massive regional and subtype- dependent regulation
	Thüne Katrin Department of Neurology, Medical University Göttingen, Germany; German Center for Neurodegenerative Diseases (DZNE)
P-091	Variant CJD: Lessons in Public Health
	Abigail B Diack The Roslin Institute, University of Edinburgh, United Kingdom
P-092	Identification of new molecular alterations in Fatal Familial Insomnia
	Isidro Ferrer University of Barcelona; Institute of Neuropathology, Bellvitge University Hospital, Hospitalet de Llobregat, Spain; CIBERNED, Institute Carlos III, Spain
P-093	An autopsy case of MM1-type sporadic Creutzfeldt-Jakob disease with 1-month total disease duration presenting with early disease pathology
	Yasushi Iwasaki Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Japan
P-094	Familial Creutzfeldt-Jacob disease (V180I) as the initial presenting depression: Case report
	Dooeung Kim Neurology, Veterans Hospital, Seoul Medical Center, Korea
P-095	A survey of anti-prion compounds using the real time-quaking induced conversion (RT- QuIC)
	Jae Wook Hyeon National Institute of Health (Korea CDC), Korea
P-096	Proteomics Analyses for the Global Proteins in the Brain Tissues of Different Human Prion Diseases
	Qi Shi Prion Department, National Institute for Viral Disease Control and Prevention, China CDC, China

P-097	Genetic Creutzfeldt-Jacob disease with V180I mutation in Korea Jae W Kim Dong-A University, Korea
P-098	Genome differences between genetic Creutzfeldt-Jakob Disease's patients with V180I mutation and healthy individuals and associations with other neurodegenerative disorders Sol Moe Lee Division of Zoonoses, Center for Immunology & Pathology, National Institute of Health, Korea Centers for Disease Control & Prevention, Korea
P-099	A Therapeutic Approach for Creutzfeldt-Jakob Disease by DNAzyme-mediated Knockdown of the Prion Protein Julian Victor Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Germany
P-100	Differential association of amyloid-β with PrP ^{sc} pathology in each genetic prion disease Fumiko Furukawa Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, Japan
P-101	Withdrawn
P-102	Brain Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Neuropathologic Correlations in Human Prion Diseases Brian S Appleby Case Western Reserve University, National Prion Disease Pathology Surveillance Center, United States
P-103	Celia´s encephalopathy: A new member of the group of protein misfolding-mediated neurodegenerative diseases Jesús R. Requena University of Santiago de Compostela, Spain
P-104	AR-12 and its derivatives, a potential new therapeutic agent against prions Hermann M Schatzl University of Calgary, Comp. Biol. & Exp. Med., Canada
P-105	An autopsy-verified case of FTLD-TDP with upper motor neuron predominant motor neuron disease mimicking MM2-thalamic-type sporadic Creutzfeldt-Jakob disease Yuichi Hayashi Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Japan
P-106	Temporal resolution of PrP ^{sc} transport, PrP ^{sc} accumulation, activation of glia and neuronal death in retinas from C57Bl/6 mice inoculated with RML scrapie: Relevance to biomarkers of prion disease progression M. Heather West Greenlee Biomedical Sciences, Iowa State University College of Veterinary Medicine, United States
P-107	CSF analysis of patients with human prion disease Katsuya Satoh Department of Locomotive Rehabilitation Science, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan
P-108	Prospective surveillance data of human prion disease in the Chugoku and Shikoku regions of Japan Kota Sato Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan



P-109	Tau / p-Tau and the altered regulatory response of Rab7a contributing the fast progression rate in Creutzfeldt-Jakob disease (CJD) and rapid progressive Alzheimer's disease (rpAD) Saima Zafar Department of Neurology, Clinical Dementia Center and DZNE, Georg-August University, University Medical Center Goettingen (UMG), Germany
P-110	Detection of disease-specific PrP and infectivity in the blood of mice with preclinical prion disease - implications and applications for public health Elizabeth B Sawyer MRC Prion Unit, United Kingdom
P-111	Iatrogenic Creutzfeldt-Jakob disease in human growth hormone recipients in the United Kingdom Mark W Head National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom
P-112	Assessing the disease-modifying role of TREM2 in a prion model of neurodegeneration Jean C Manson The Roslin Institute, United Kingdom
P-113	Two International Ring-trials demonstrate that CSF RT-QuIC is a robust and reliable test for diagnosing sporadic CJD Neil I. McKenzie University of Edinburgh, National CJD Research and Surveillance Unit, Western General Hospital, Edinburgh, United Kingdom
P-114	Enhanced Creutzfeldt-Jakob disease surveillance in the older population in the UK: Biochemical analysis for PrP ^{sc} Helen M Yull National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, UK
P-115	Accuracy of Creutzfeldt-Jakob disease diagnosis using RT-QuIC testing of nasal and cerebrospinal fluid samples Gianluigi Zanusso University of Verona, Department of Neurosciences, Biomedical and Motor Sciences, Italy
P-116	A novel approach combining 3D human cell culture and 3D microscopy to assess prion infectivity Ferid Nassor CEA DRF/iMETI/SEPIA, Fontenay-aux-Roses, France
P-117	Iatrogenic CJD after human GH treatment in France: Effect of sex, dose and genetics on the susceptibility of a possible infection by a V2 sCJD strain Laurene Peckeu Team Alzheimer's and Prion Diseases, Inserm UMR-1127/CNRS UMR 7225, Université Pierre & Marie Curie - Paris 6, France
P-118	Volumetric analysis and Diffusion Tensor Imaging in Creutzfeldt-Jakob disease and fatal insomnia point to the thalamus as a key structure in disease pathogenesis Oriol Grau-Rivera Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Spain
P-119	Prion protein interactome: Identifying novel targets in rapidly progressive Alzheimer's disease Mohsin Shafiq Clinical Dementia Center, Department of Neurology and Psychiatry, University Medical Center Goettingen, Germany
P-120	Assessment of doxycycline treatment on prion deposition in the olfactory epithelium of patients with Fatal Familial Insomnia: Possible mirroring of the CNS alterations Fabio Moda IRCCS Foundation Carlo Besta Neurological Institute, Department of Neuropathology and Neurology, Italy

P-121	Unusually young prion disease cases in the United States, 1979-2014 Ryan A. Maddox National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), USA
D 122	
P-122	End-Point Quaking-Induced Conversion (EP-QuIC) as a Routine Test for sCJD in Canada
	Public Health Agency of Canada, Canada; Department of Medical Microbiology, University of Manitoba
P-123	Rapid testing for Creutzfeldt-Jakob disease in donors of human tissues
	David M. Asher US Food and Drug Administration, Center for Biologics Evaluation and Research, United States
P-124	Rational design and optimization of drug leads targeting prion-like misfolding and aggregation of SOD1 enzyme in Amyotrophic Lateral Sclerosis Vijaya Kumar Hinge
	National Institute for Nanotechnology, Canada; Department of Mechanical Engineering, University of Alberta, Alberta, Canada
P-125	Novel detection technique of early Alzheimer's disease from blood using fluorescence spectral microscopy
	Shigeki Tsutsui Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada
P-126	Geographic risk of variant Creutzfeldt-Jakob disease: A risk ranking model to evaluate options for blood donor deferral policies in the US
	Hong Yang US Food and Drug Administration, United States
P-127	Early response of Cofilin1 pathway in Creutzfeldt Jakob disease
	Neelam Younas Department of Neurology, Clinical Dementia Center and DZNE, Georg-August University, University Medical Center Goettingen (UMG), Germany
P-128	Clinical courses of patients with Creutfeldt-Jakob disease in Shizuoka Institute of Epilepsy and Neurological Disorders, Japan
	Tomokazu Obi Shizuoka Institute of Epilepsy and Neurological Disorders, Department of Neurology, Japan
P-129	Epidemiologic features of human prion diseases in Japan: A prospective 15-year surveillance study
	Ryusuke Ae Division of Public Health, Center for Community Medicine, Jichi Medical University, Japan
P-130	Diagnostic significance of Periodic synchronous discharges in Japanese surveillance of Creutzfeldt-Jakob disease
	Yoshiyuki Kuroiwa Teikyo University Mizonokuchi Hospital, Japan
P-131	Creutzfeldt-Jakob disease associated with a V203I homozygous mutation in the prion protein gene Junji Komatsu
	Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan
P-132	Clinical features in the patients with V180I, M232R and P102L of PRNP Erika Abe Neurology, National Hospital Organization Akita Hospital, Japan
P-133	Suspected prion disease cases referred to the National Prion Disease Pathology
	Surveillance Center, United States Ermias D Belay Centers for Disease Control and Prevention, Atlanta, Georgia, United States



P-134	CSF biomarkers, Tau and 14-3-3, in genetic and sporadic Creutzfeldt-Jakob disease patients in Israel
	Zeev Meiner Physical Medicine and Rehabilitation, Hadassah-Hebrew University Hospital, Israel
P-135	The Japanese Consortium of Prion Disease (JACOP) for patients' registration and clinical studies of Prion diseases in Japan
	Yuko Ishimura National Center Hospital, National Center of Neurology and Psychiatry, Japan
P-136	Cerebral beta-amyloidosis in patients with dura mater graft-associated Creutzfeldt- Jakob disease
	Tsuyoshi Hamaguchi Department of Neurology, Kanazawa University Hospital, Japan
P-137	Withdrawn
P-138	Clinically and neuropathologically atypical autopsied case of sporadic Creutzfeldt- Jakob disease MM type1 Yuta Nakano
	Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institution of Gerontology, Japan
P-170	CJD International Support Alliance (CJDISA) - The voice, the face, the human story behind this horrific disease
	Suzanne Solvyns CJD International Support Alliance, Australia; CJD Support Group Network Australia; CJD Insight; CJD Foundation USA; CJD Support Network Japan; CJD Support Network UK; A.I.En.P. Italy; MCJ-HCC France; CJK Initiative e.V. Germany; CJD Foundation Israel
P-139	How can we increase the number of prion autopsy in Japan? Masaki Takao Saitama International Medical Center; Mihara Memorial Hospital, Japan
P-140	Wire-QuIC: A new detection system of human prion
	Tsuyoshi Mori Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan
P-141	The first Italian case of Creutzfeldt-Jakob disease with V180I mutation in the PrP gene (PRNP)
	Maurizio Pocchiari Istituto Superiore di Sanità, Cell Biology and Neurosciences, Italy
P-142	Evaluation of CSF RT-QuIC diagnostic assay for Creutzfeldt-Jakob and other human prion diseases: The Italian Surveillance Unit experience
	Maurizio Pocchiari Istituto Superiore di Sanità, Cell Biology and Neurosciences, Italy
P-143	A case of slowly progressive familial prion disease with a five-octapeptide repeat insertion
	Makoto Takahashi Department of Neurology, Kanto Central Hospital, Japan
P-144	Human Prion Diseases Surveillance and Registration System in Japan
	Tadashi Tsukamoto Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan
P-171	Presymptomatic genetic testing for genetic prion disease: What should we consider and how should we deal with it?
	Chieko Tamura FMC Tokyo Clinic, Japan; Genetic Counseling Clinic, Juntendo University Hospital

EP-022	Agraphia of Kanji (Chinese characters): An early symptom of sporadic Creutzfeldt- Jakob disease in a Japanese patient Keiko Nakamura
	Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan
EP-023	Establishment of high-sensitivity detection method of FABP3 in cerebrospinal fluid of CJD patients
	Yumi Tanaka Department of Molecular and Applied Biosciences, Hiroshima University Graduate School of Biosphere Science, Japan
EP-024	Annual incidence of Gerstmann-Stäussler-Scheinker disease in Kyushu region of Japan Yoshio Tsuboi Department of Neurology, Fukuoka University, Japan
EP-025	Generation of Alzheimer's disease (AD) genetic patients reprogrammed stem cells (iPS) as tools for the study of AD physiopathology
	Laura Auboyer Institute for Regenerative Medicine and Biotherapy (IRMB), France
EP-026	SPECT study of the Nigrostriatal Dopaminergic System in Creutzfeldt-Jakob disease: A case report and literature review
	Tzu-Hsuan Chen Department of Physical Medicine and Rehabilitation,Shin Kong Wu Ho-Su Hospital, Taipei, Taiwan
EP-027	Epidemiological survey of Gerstmann-Straussler-Scheinker disease with codon 102 mutation in Japan
	Hiroyuki Murai Department of Neurological Therapeutics, Kyushu University, Japan
EP-028	A case of subacute progressive dementia presenting with M129V mutation of the prion protein gene and positive RT-QUIC assays Rie Motoyama
	Neurology, Tokyo Metropolitan Geriatric Hospital, Japan
EP-029	Inhibition of The interaction between Prion Protein and Amyloid beta protein by Computational Methods; A strategy Against Alzheimer's Disease Michael K Fonjang
	German School for Simulation Science (GRS), Cameroon
P-145	Estimating chronic wasting disease resistance in cervids using real time quaking- induced conversion
	Nicholas J Haley Department of Microbiology and Immunology, Midwestern University, United States
P-146	RT-QUIC detection in CWD infected cervid and TgElk mice tissues Hyun Joo Sohn
P-147	Animal and Plant Quarantine Agency (QIA), Korea
F-147	Hyun Joo Sohn Animal and Plant Quarantine Agency (QIA), Korea
P-148	Prion treatment by electrolyzed alkaline water and other chemicals Takashi Onodera University of Tokyo, Japan
P-149	Key Features of the Australian BSE Food Safety Assessment Process Hong Jin Food Standards Australia New Zealand, Australia

PRION 2016 T●KYO	6
P-150	Study of the allelic variants at codon 222 in the genome goat for the detection of susceptibility to SCRAPIE, through the mass spectrometry (MALDI-TOF) Daniele Macri' Istituto Zooprofilattico Sperimentale della Sicilia, Italy
P-151	Phenotypic plasticity of chronic wasting disease prions Christina M Carlson U.S. Geological Survey National Wildlife Health Center, United States
P-152	Sensitive and Rapid Diagnosis of Goat Prion Diseases by Real Time Quaking Induced Conversion Assay Alessandra Favole Istituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta, Italy
P-153	Experimental oral transmission of chronic wasting disease to sika deer (Cervus nippon) Gordon Mitchell National & OIE Reference Laboratory for Scrapie and CWD, Canadian Food Inspection Agency, Ottawa, Ontario, Canada
P-154	Prion infectivity detected in swine challenged with chronic wasting disease via the intracerebral or oral route S Jo Moore Virus and Prion Research Unit, National Animal Disease Center, ARS, USDA, United States
P-155	Oral Transmission of Classical BSE to Adult Cattle Sandor Dudas Canadian and OIE BSE Reference Laboratory, Canadian Food Inspection Agency, National Center for Animal Disease Lethbridge, Canada
P-156	Detection of Prion Protein Specific Camelid Nanobodies: Implications for Prion Disease Therapeutic Options Savannah M Rocha Colorado State University, United States
P-157	Earthworms can act as carriers for prion disease transmission Sandra Pritzkow University of Texas Health Science Center at Houston, Germany; Mitchell Center for Alzheimer's Disease and Related Brain Disorders
P-158	Prion Protein Gene Sequences Analysis in Twelve Sheep Breeds of Pakistan Mohammad Farooque Hassan China Agricultural University, Beijing, China; SBBUVAS, Sakrand Sindh, Pakistan
P-159	The epidemiological evolution of prion infection on bovine in Romania, in the period of 2010 - 2015 Florica Barbuceanu Institute for Diagnosis and Animal Health, Romania; Faculty of Veterinary Medicine Bucharest
P-160	Rapid tests might overlook bovine spongiform encephalopathy infection in goats Daniela Meloni CEA, Istituto Zooprofilattico Sperimentale dl Piemonte, Liguria e Valle d'Aosta, Turin, Italy
P-161	A high incidence of atypical scrapie in a closed flock of Cheviot sheep Fiona Houston Neurobiology Division, The Roslin Institute, University of Edinburgh, United Kingdom
P-162	Local and Traditional Knowledge in Monitoring of Chronic Wasting Disease and Wildlife Health in Western Canada Brenda L Parlee Dept. Resource Economics & Env. Sociology, Faculty of Agricultural, life and Environmental Sciences, University of Alberta, Canada

EP-010	Simplified Rapid Detection of Prions in Biological Fluids Using Particle Extraction and Real-time Quaking Induced Conversion
	Nathaniel D Denkers Colorado State University, Dept. Microbiology, Immunology, and Pathology, United States
EP-011	Neuronal death and prion diseases
	Corinne I Lasmezas Department of Immunology and Microbial Science, Department of Neuroscience, The Scripps Research Institute, United States
EP-012	Delipidation of brain tissue partially removed the inhibitory effect of prion amyloid formation
	Yoshifumi Iwamaru National Institute of Animal Health, Japan
EP-013	Withdrawn
P-163	Active vaccination against chronic wasting disease using multimeric rec-PrP: A promising approach to contain CWD Dalia HA Abdelaziz
	Department of Comparative Biology & Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Alberta, Canada
P-164	Adsorption of Soluble Prions by Metals Is Limited by Plasma
	Maurizio Pocchiari Istituto Superiore di Sanità, Italy
P-165	CJD incidents in Japan
	Ichiro Takumi Department of Neurosurgery, Nippon Medical School Musashi Kosugi Hospital, Japan; Japan CJD Indecent Committee
P-166	Inactivation of atypical and classical BSE prions by laboratory-scale autoclaving
	James Hope Animal and Plant Health Agency, United Kingdom
P-168	Three-dimensional cultures of murine neurones demonstrate prion-induced plaque pathology and cell death
	Cathryn L Haigh Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Australia
P-169	Building a Program for Community-Based Monitoring of Wildlife Health - Lessons for Surveillance of Chronic Wasting Disease in Moose and Deer in Western Canada
	Brenda L. Parlee Dept. of Resource Economics and Environmental Sociology, Faculty of Agricultural, life and Environmental Sciences, University of Alberta, Canada
EP-020	Prion seeding activity is widely distributed in tissues of sporadic Creutzfeldt-Jakob disease patients
	Katsuya Satoh Department of Locomotive Rehabilitation Science, Nagasaki University Graduate School of Biomedical Sciences, Japan
EP-021	Canine Prions: A New Form of Prion Disease
	Mourad Tayebi University of Melbourne, Veterinary Sciences, Australia